Reconstitution of human organogenesis on microchips

Lecture / Panel
For NYU Community

Image of lungs


Edwin Rosado-Olivieri, PhD
Assistant Professor, Dept. of Molecular Pathobiology
Division of Biomaterials and Regenerative Biology, NYU College of Dentistry


Edwin Rosado-Olivieri is a stem cell, developmental and regenerative biologist, studying the mechanisms that choreograph human organ development and function. In humans, how developing organs coordinate tissue morphogenesis and cellular differentiation remains poorly understood. His laboratory seeks to unravel the cellular and molecular underpinnings of human organogenesis. Their research focuses on the development of stem cell-based models, computational, and genetic approaches to uncover fundamental aspects of human development and disease. They specialize in the development of innovative stem cell-based mini-organ models and high-throughput quantitative paradigms to explore and understand the complexities of human organ development. The goal is to use this research to shed light on how these processes are dysregulated in human diseases, ultimately leading to more effective treatments and better outcomes for patients. Their approach provides an innovative and quantitative framework for interrogating fundamental aspects of human embryology, which will ultimately enhance the in vitro derivation of human cells for disease modeling and clinical applications.

Dr. Rosado-Olivieri received his B.Sc. in Cellular and Molecular Biology from the University of Puerto Rico, in 2014, and his Ph.D. in Developmental and Regenerative Biology for the Department of Stem Cell and Regenerative Biology at Harvard University in 2019. Subsequently he pursued a Postdoctoral Fellowship in the Laboratory of Synthetic Embryology at The Rockefeller University in New York. He has received multiple awards for his innovative work, including the Blavatnik Biomedical Accelerator Award (2019), the Merit Award from the International Society for Stem Cell Research (2019), and the Robertson Therapeutic Develop-ment Fund Commercialization Award (2021). In addition, he co-founded RumiViro, a company that is developing therapeutics targeting respiratory viruses and chronic kidney diseases

Image of Mini Organs
Low-magnification images of epithelial buds containing NK32.1+ lung progenitors grown on confined geometries of 225-mm diameter at high doses of KGF (50 ng/mL).